HOME ȸ»ç¼Ò°³ ½ÃÀÛÆäÀÌÁö·Î Áñ°Üã±âÃß°¡ ±âÀÚȸ¿ø½Åû
[¸ð¹ÙÀϸðµå] ·Î±×ÀΠȸ¿ø°¡ÀÔ
2024³â05¿ù07ÀÏtue
±â»çÃÖÁ¾ÆíÁýÀÏ: 2024-05-07 18:09:06
´º½ºÈ¨ > ±â°ü/´Üü > ÀǼöÇù
2009³â10¿ù21ÀÏ 00½Ã00ºÐ
±ÛÀÚÅ©±â ±â»ç³»¿ë À̸ÞÀϺ¸³»±â ´º½ºÇÁ¸°Æ®Çϱ⠴º½º½ºÅ©·¦Çϱâ
ÀǼöÇù, SCI ±¹Á¦ÇмúÁö¿¡ ³í¹® 2Æí µîÀç
Çѱ¹ÀǾàÇ°½ÃÇ迬±¸¼Ò ¿¬±¸±â¼ú·Â ±¹Á¦Àû ÀÎÁ¤

Çѱ¹ÀǾàÇ°¼öÃâÀÔÇùȸ (ȸÀå ÀÌÀ±¿ì) ºÎ¼³ Çѱ¹ÀǾàÇ°½ÃÇ迬±¸¼Ò »ýµ¿¼º¿¬±¸ºÎ¿¡¼­ Àú¸íÇÑ ±¹Á¦ÇмúÁöÀÎ Journal of Bioequivalence & Bioavailability¿¡ Á¦ÃâÇÑ ³í¹®ÀÌ Ã¤ÅõŠ2009³â 9¿ù 4ÀÏÀÚ·Î ¹ßÇ¥µÆ´Ù. ÀÌ ³í¹®ÀÇ Á¦¸ñÀº 'Pharmacokinetic profiles of two branded formulations of piroxicam 20 mg in healthy Korean volunteers by a rapid isocratic HPLC method'(Á¦1ÀúÀÚ ¼ÛÇöÈ£ ÁÖÀÓ¿¬±¸¿ø)·Î ÇǷϽÃįÀÇ ÃֽŠºÐ¼®¹ýÀ» ¿¬±¸ÇÏ°í À̸¦ Å©¶ó¿îÁ¦¾à ÇǷϽÃįÁ¦Á¦ÀÇ »ý¹°ÇÐÀûµ¿µî¼º½ÃÇè¿¡ Àû¿ëÇØ »ýµ¿¼ºÀ» ÀÔÁõÇß´Ù.

¹ßÇ¥µÈ ³í¹®¿¡ µû¸£¸é ÇǷϽÃį ºÐ¼®¿¡ ¼Ò¿äµÇ´Â ½Ã°£ (running time)ÀÌ ÀϹÝÀûÀ¸·Î HPLCÀÇ °æ¿ì 15 ~ 20ºÐ ¼Ò¿äµÇ°í, LC/MS/MSÀÇ °æ¿ì 6ºÐÀÌ ¼Ò¿äµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª, ÀǼöÇùÀº °íµµÀÇ ¿¬±¸±â¼ú·ÂÀ¸·Î HPLC¸¦ »ç¿ëÇØ ºÒ°ú 2ºÐ À̳»¿¡ ºÐ¼®À» ¿Ï·áÇß´Ù. Ç÷Àå½Ã·á¼ö°¡ 1000¿©°Ç¿¡ ´ÞÇÏ´Â »ýµ¿¼º½ÃÇèÀÇ °æ¿ì º¸´Ù ½Å¼Ó, Á¤È®ÇÑ °á°ú µµÃâÀÌ °¡´ÉÇØÁø °ÍÀÌ´Ù.
 
Àú¸í SCI ÀÓ»óÇмúÁöÀÎ Clinical Therapeutics (impact factor 3.06)¿¡ Á¦ÃâÇÑ ³í¹®µµ 2009³â 9¿ù äÅõưí, 11¿ùÈ£¿¡ ¹ßÇ¥µÉ ¿¹Á¤ÀÌ´Ù. Á¦¸ñÀº 'The Bioequivalence or Relative Bioavailability of 250 mg and 500 mg Oral Chlorphenesin Carbamate Tablets in Healthy Korean Adult Volunteers in an Open-Label, Single-Dose, Randomized Two-Period, Cross-Over Trial'(Á¦1ÀúÀÚ À¯Áö¿µ ÁÖÀÓ¿¬±¸¿ø)·Î Ŭ·Î·ÎÆä³×½Å 250 mg°ú 500 mgÀ» °æ±¸ º¹¿ëÇßÀ» ¶§, Çѱ¹Àο¡ ´ëÇÑ ¾à¹°µ¿·ÂÇÐÀ» ºñ±³ ¿¬±¸ÇÑ ³í¹®ÀÌ´Ù. ºÐ¼®¹ý¿¡¼­´Â HPLC¸¦ »ç¿ëÇßÀ» ¶§ ÀϹÝÀûÀ¸·Î Ç÷Àå½Ã·á 1°³´ç 10ºÐ ÀÌ»ó ¼Ò¿äµÇ´Â ºÐ¼®À» ÀǼöÇù¿¡¼­´Â 6ºÐ À̳»¿¡ Á¤È®ÇÑ ºÐ¼®À» ¿Ï·áÇØ ÇмúÁö ½É»çÀ§¿øµéÀÇ È£ÆòÀ» ¹Þ¾Ò´Ù.

±³½ÅÀúÀÚÀÎ ±Ç¿µÀ̹ڻç (»ýµ¿¼º¿¬±¸ºÎÀå, Àü ¿ì¼®´ë ¾àÇаú ±³¼ö)´Â À̹ø SCI±¹Á¦ÇмúÁö ³í¹®¹ßÇ¥´Â Çѱ¹ÀǾàÇ°½ÃÇ迬±¸¼ÒÀÇ ¿¬±¸±â¼ú·ÂÀ» ±¹Á¦»çȸ¿¡¼­ ÀÎÁ¤¹ÞÀº °ÍÀ̶ó°í Çß´Ù.

ÀǼöÇùÀº ÇöÀç Ư¼öÁ¦Çü ¹× º¹ÇÕÁ¦ »ýµ¿¼º µî º¸´Ù ¿ì¼öÇÑ ±â¼ú·ÂÀ» ¿äÇÏ´Â Á¦Á¦¿¡ ´ëÇÑ ¼º°øÀûÀÎ ¿¬±¸¸¦ ¼öÇàÇÏ°í ÀÖÀ¸¸ç, ÀÌ ¿¬±¸°á°úµé ¿ª½Ã SCI¿¡ ¹ßÇ¥ÇÒ °ÍÀ̶ó°í ¹àÇû´Ù.  

 

°ü·Ã±â»ç°¡ ¾ø½À´Ï´Ù
´º½º½ºÅ©·¦Çϱâ
°­µ¿Áø (webmaster@bktimes.net) ±âÀÚ 
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
ÀǼöÇù¼½¼Ç ¸ñ·ÏÀ¸·Î
ÀǼöÇù, ¡®ùÛ-ñé ÀǾàÇ° ±³...
ÀǼöÇù, È­ÀåÇ° Ã¥ÀÓÆǸŰü...
ÀǼöÇù, ÀϺ» Àεµ³×½Ã¾Æ ...
ÀǼöÇù, ű¹¼­ Bio - IT ...
Çѱ¹ÀǾàÇ°½ÃÇ迬±¸¼Ò¤ýÇÑ...
´ÙÀ½±â»ç : ÀǼöÇù, EU Áß³²¹Ì ÀǾàÇ° ½ÃÀå ÁøÃâ ¼³¸íȸ °³ÃÖ (2009-11-12 00:00:00)
ÀÌÀü±â»ç : ÀǼöÇù, ű¹¼­ Bio - IT ¼öÃâ»ó´ãȸ °³ÃÖ (2009-10-09 00:00:00)
º´¿ø°è, "°è...
º´¿ø°è, "°è¹¦³â...
Á¦¾à¡¤°Ç½Ä 12°³...
°Çº¸°ø´Ü, ¼Ò¼Ó±â°ü '¼­¿ï¿ä¾ç...
¼ºÀåÇÏ°íÇ ´ç½Å, "Áö±Ý ´ë¿õ,...
º¸·ÉÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷Á÷ ...
°Çº¸°ø´Ü, ¿ÃÇØ '°³¹æÇü Á÷°ú ...
°Çº¸°ø´Ü, '¿Ã Á¦3Â÷ °³¹æÇü ...
³í¹®) Cancer Risk in Graves Disease with Radioacti...  
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸º¸È£Á¤Ã¥ ÀÌ¿ë¾à°ü À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ ¾Ë¸³´Ï´Ù º¸µµÀÚ·á ±â»çÁ¦º¸ Á¤±â±¸µ¶